Background Background The extentto which
The extentto which atypical antipsychotics have a lower atypical antipsychotics have a lower incidence of extrapyramidal symptoms incidence of extrapyramidal symptoms than typical antipsychotics has not been than typical antipsychotics has not been well-evaluated in community practice. well-evaluated in community practice.
Aims Aims To examine the effects of
To examine the effects of switching antipsychotics on antiswitching antipsychotics on antiparkinsonian medication use among parkinsonian medication use among individuals with schizophrenia in UK individuals with schizophrenia in UK general practices. general practices.
Method Method We included those switched
We included those switched from typical to atypical antipsychotics from typical to atypical antipsychotics ( (n n¼209) or from one typical antipsychotic 209) or from one typical antipsychotic to another ( to another (n n¼261) from1994 to1998.
261) from1994 to1998.
Results
Results Antiparkinsonian drug Antiparkinsonian drug prescribing dropped by 9.2% after prescribing dropped by 9.2% after switching to atypical antipsychotics switching to atypical antipsychotics ( (P P5 50.0001). Switching to olanzapine 0.0001). Switching to olanzapine decreased the rate by19.2% ( decreased the rate by19.2% (P P5 50.0001), 0.0001), but switching to risperidone had no but switching to risperidone had no impact. After switching from one typical impact. After switching from one typical antipsychotic to another, antiparkinsonian antipsychotic to another, antiparkinsonian drug prescribing increased by12.9% drug prescribing increased by12.9% ( (P P5 50.0001). 0.0001).
Conclusions Conclusions Reduction in
Reduction in antiparkinsonian medication use after antiparkinsonian medication use after switching to atypical antipsychotics was switching to atypical antipsychotics was substantial in community practice but not substantial in community practice but not as large as in randomised controlled trials. as large as in randomised controlled trials. The rate of reduction varied according to The rate of reduction varied according to the type of medication. the type of medication.
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Extrapyramidal symptoms are the most Extrapyramidal symptoms are the most common reason for non-adherence to common reason for non-adherence to schizophrenia treatment, leading to treatschizophrenia treatment, leading to treatment failures and preventable morbidity, ment failures and preventable morbidity, mortality and economic costs (Knapp, mortality and economic costs (Knapp, 1997; Lindstrom & Bingefors, 2000 ). 1997 Lindstrom & Bingefors, 2000) . The majority of studies reporting that The majority of studies reporting that atypical antipsychotics are less likely to atypical antipsychotics are less likely to cause extrapyramidal symptoms than cause extrapyramidal symptoms than typical antipsychotics are clinical trials typical antipsychotics are clinical trials (Tran (Tran et al et al, 1999; Bouchard , 1999; Bouchard et al et al, 2000; , 2000 ; Costa e Silva Costa e Silva et al et al, 2001; Inada , 2001; Inada et al et al, , 2001; Ritchie 2001; Ritchie et al et al, 2003) . However, those , 2003) . However, those with schizophrenia have a high degree of with schizophrenia have a high degree of comorbidity (Buckley comorbidity (Buckley et al et al, 1999) and low , 1999) and low adherence rates (Lindstrom & Bingefors, adherence rates (Lindstrom & Bingefors, 2000) , which are often not reflected in 2000), which are often not reflected in clinical trials, but have an important influclinical trials, but have an important influence on treatment outcome. Observational ence on treatment outcome. Observational studies have not evaluated the long-term studies have not evaluated the long-term effectiveness of antipsychotics on extraeffectiveness of antipsychotics on extrapyramidal symptoms (Bobes pyramidal symptoms (Bobes et al et al, 2003; , 2003; Montes Montes et al et al, 2003; Soholm & Lublin, , 2003; Soholm & Lublin, 2003) , although antipsychotics are gener-2003) , although antipsychotics are generally used indefinitely. Most observational ally used indefinitely. Most observational studies have included only in-patients studies have included only in-patients (Coley (Coley et al et al, 1999; Barak , 1999; Bobes , 2002; Bobes et al et al, 2003; Soholm & Lublin, 2003 ), but , 2003 Soholm & Lublin, 2003) , but many chronically ill individuals with schizomany chronically ill individuals with schizophrenia receive maintenance pharmacophrenia receive maintenance pharmacotherapy in primary care (Lang therapy in primary care (Lang et al et al, 1997; , 1997; Freedman, 2003) . This study evaluates the Freedman, 2003) . This study evaluates the use of antiparkinsonian medication before use of antiparkinsonian medication before and after switching antipsychotics in a and after switching antipsychotics in a community population of individuals with community population of individuals with schizophrenia in UK general practices. schizophrenia in UK general practices. 
METHOD METHOD Data Data

Study group Study group
We studied 6356 individuals from 266 genWe studied 6356 individuals from 266 general practices who had been diagnosed with eral practices who had been diagnosed with schizophrenia and prescribed antipsychoschizophrenia and prescribed antipsychotics between 1992 and 2000. Schizophrenia tics between 1992 and 2000. Schizophrenia diagnoses were derived from the records of diagnoses were derived from the records of out-patient contacts with general practiout-patient contacts with general practitioners. We focused on those who had been tioners. We focused on those who had been switched from typical to atypical antiswitched from typical to atypical antipsychotics (TA group) or from typical to psychotics (TA group) or from typical to different typical antipsychotics (T  different typical antipsychotics (TT group) T group) between 1994 and 1998, and who were between 1994 and 1998, and who were present in the database for at least 2 years present in the database for at least 2 years before and after the switch. Only those before and after the switch. Only those who were diagnosed with schizophrenia at who were diagnosed with schizophrenia at least 2 years before the switch were evaluleast 2 years before the switch were evaluated. We defined the TA group as those ated. We defined the TA group as those who had been prescribed typical antiwho had been prescribed typical antipsychotics before the switch, completely psychotics before the switch, completely stopped typical antipsychotics and subsestopped typical antipsychotics and subsequently switched to atypical antipsychotics, quently switched to atypical antipsychotics, with no typical antipsychotic use for at with no typical antipsychotic use for at least 2 years after the switch. The T least 2 years after the switch. The TT group T group included patients who were prescribed one included patients who were prescribed one typical antipsychotic (e.g. chlorpromazine) typical antipsychotic (e.g. chlorpromazine) and then switched to a different typical and then switched to a different typical antipsychotic (e.g. haloperidol), and who antipsychotic (e.g. haloperidol), and who never received an atypical antipsychotic. never received an atypical antipsychotic. The analysis included 209 in the TA group The analysis included 209 in the TA group and 261 in the T and 261 in the TT group.
T group. Because risperidone and olanzapine Because risperidone and olanzapine were the most commonly prescribed (87%) were the most commonly prescribed (87%) atypical antipsychotics after the switch in atypical antipsychotics after the switch in the TA group, we also focused on those the TA group, we also focused on those within that group who had been switched within that group who had been switched from typical antipsychotics to either of from typical antipsychotics to either of these two atypical antipsychotics. Using these two atypical antipsychotics. Using the same inclusion criteria as above, we dethe same inclusion criteria as above, we defined the risperidone, TA fined the risperidone, TA R R (or olanzapine, (or olanzapine, TA TA O O ) recipients as those who had been ) recipients as those who had been prescribed typical antipsychotics with prescribed typical antipsychotics with no atypical antipsychotics before the no atypical antipsychotics before the switch, and then switched to either switch, and then switched to either -2003) . The antiparkinsonian drug prescribing rate was calculated as the number cribing rate was calculated as the number of individuals during an observation of individuals during an observation period who were prescribed an antiparkinperiod who were prescribed an antiparkinsonian drug divided by the number in sonian drug divided by the number in each switching group. We adjusted gender each switching group. We adjusted gender and age to the combined study population and age to the combined study population at the time of switching. Because at the time of switching. Because individuals switched at different times, the individuals switched at different times, the quarter when the switch occurred was quarter when the switch occurred was treated as the start of the follow-up period treated as the start of the follow-up period ('point 0').
('point 0'). We also examined the mean daily dose We also examined the mean daily dose of antiparkinsonian drugs prescribed for 2 of antiparkinsonian drugs prescribed for 2 years before and after switching. We years before and after switching. We analysed only tablets and capsules, which analysed only tablets and capsules, which accounted for 98% of all antiparkinsonian accounted for 98% of all antiparkinsonian drug prescriptions. Daily dose was estidrug prescriptions. Daily dose was estimated by dividing total dose by duration mated by dividing total dose by duration of antiparkinsonian medication use before of antiparkinsonian medication use before and after the switch. Only the TA and T and after the switch. Only the TA and TT T groups were investigated because of the groups were investigated because of the small sample sizes for the two subgroups. small sample sizes for the two subgroups.
Statistical analyses Statistical analyses
We conducted interrupted time series We conducted interrupted time series analyses to estimate changes in the rates analyses to estimate changes in the rates of prescribing of antiparkinsonian drugs of prescribing of antiparkinsonian drugs after drug switching, controlling for the after drug switching, controlling for the trend before the switch (SAS Institute, trend before the switch (SAS Institute, 2000 2000a a; Wagner ; Wagner et al et al, 2002) . Our models , 2002). Our models included the trend in the rate of antiparkinincluded the trend in the rate of antiparkinsonian drug prescribing before the switch, sonian drug prescribing before the switch, and changes in the trend and level of antiand changes in the trend and level of antiparkinsonian drug prescribing after switchparkinsonian drug prescribing after switching. The switch point quarter (point 0) was ing. The switch point quarter (point 0) was excluded from analyses because it was not excluded from analyses because it was not clear whether the outcome in that quarter clear whether the outcome in that quarter resulted from antipsychotics used before resulted from antipsychotics used before or after switching. We used or after switching. We used t t-tests to -tests to compare the mean daily dose of antiparkincompare the mean daily dose of antiparkinsonian drugs before and after the switch sonian drugs before and after the switch (SAS Institute, 2000 (SAS Institute, 2000b . ).
We used SAS Version 8.2 for all statisWe used SAS Version 8.2 for all statistical analyses. All statistical analyses were tical analyses. All statistical analyses were performed separately for each group. performed separately for each group. Table 1 summarises the characteristics of Table 1 summarises the characteristics of the study population. Those in the TA the study population. Those in the TA group were more likely to be male, whereas group were more likely to be male, whereas those in the T those in the TT group were more likely to T group were more likely to be female ( be female (w w 2 2 ¼8.54, d.f.
RESULTS RESULTS
Patient characteristics Patient characteristics
8.54, d.f.¼1, 1, P P¼0.004). 0.004). Mean age of the T Mean age of the TT group was higher than T group was higher than the TA group ( the TA group (t t¼7 73.25, d.f.
3.25, d.f.¼468, 468, P P¼0.001). There were no statistically 0.001). There were no statistically significant differences in gender and age significant differences in gender and age between those switching to risperidone between those switching to risperidone or olanzapine. or olanzapine.
Individuals in the T Individuals in the TT and the TA T and the TA groups were equally likely to be cogroups were equally likely to be coprescribed other medications when preprescribed other medications when prescribed antipsychotics prior to switching, scribed antipsychotics prior to switching, including both psychoactive drugs (54.0% including both psychoactive drugs (54.0% v v. 52.6%) and other non-psychoactive . 52.6%) and other non-psychoactive drugs (75.9% drugs (75.9% v v. 76.1%). There were also . 76.1%). There were also no significant differences in baseline rates no significant differences in baseline rates of use of psychoactive and nonof use of psychoactive and nonpsychoactive medicines among those psychoactive medicines among those switched to risperidone switched to risperidone v v. olanzapine. . olanzapine.
13 8 13 8 
Age range (%) Age range (%) Figure 1 presents prescribing rates for antiparkinsonian drugs 2 years before and after parkinsonian drugs 2 years before and after the switch in the TA and T the switch in the TA and TT groups.
T groups. Controlling for baseline trends in the time Controlling for baseline trends in the time series analysis, switching from typical to series analysis, switching from typical to atypical antipsychotics was associated atypical antipsychotics was associated with a sudden drop by 9.2% in the with a sudden drop by 9.2% in the antiparkinsonian drug prescribing rate antiparkinsonian drug prescribing rate ( (t t¼7 76.10, d.f. 
DISCUSSION DISCUSSION
Using a longitudinal database of communityUsing a longitudinal database of communitybased individuals with schizophrenia, based individuals with schizophrenia, we we examined the effect of switching antipsyexamined the effect of switching antipsychotics on treatment of extrapyramidal chotics on treatment of extrapyramidal symptoms with antiparkinsonian medicasymptoms with antiparkinsonian medications. Antiparkinsonian drug prescribing tions. Antiparkinsonian drug prescribing dropped immediately after switching from dropped immediately after switching from typical to atypical antipsychotics and typical to atypical antipsychotics and continued to decrease slightly thereafter. continued to decrease slightly thereafter. Although individuals were not randomised, Although individuals were not randomised, this result confirms the findings of previous this result confirms the findings of previous clinical studies that atypical antipsychotics clinical studies that atypical antipsychotics are associated with a significantly lower are associated with a significantly lower incidence of extrapyramidal symptoms incidence of extrapyramidal symptoms and with a lower use of antiparkinsonian and with a lower use of antiparkinsonian medication than are typical antipsychotics medication than are typical antipsychotics (Tran (Tran et al In those who switched within the class of typical antiswitched within the class of typical antipsychotics, antiparkinsonian drug prescribpsychotics, antiparkinsonian drug prescribing increased immediately after the switch, ing increased immediately after the switch, but gradually decreased for 2 years therebut gradually decreased for 2 years thereafter. This suggests that physicians might after. This suggests that physicians might have prescribed antiparkinsonian drugs have prescribed antiparkinsonian drugs for prophylactic control of extrapyramidal for prophylactic control of extrapyramidal symptoms when they started to prescribe symptoms when they started to prescribe different typical antipsychotics. different typical antipsychotics.
The reduction in use of antiThe reduction in use of antiparkinsonian medication was not evenly parkinsonian medication was not evenly distributed among different atypical antidistributed among different atypical antipsychotics. Switching from typical agents psychotics. Switching from typical agents to olanzapine resulted in an abrupt decrease to olanzapine resulted in an abrupt decrease in the use of antiparkinsonian medication, in the use of antiparkinsonian medication, whereas switching to risperidone caused whereas switching to risperidone caused no change in rate. Previous studies have no change in rate. Previous studies have reported the superiority of olanzapine over reported the superiority of olanzapine over risperidone in reducing extrapyramidal risperidone in reducing extrapyramidal symptoms ( Soholm & Lublin, 2003) . Because of the difference in baseline trends in use of the difference in baseline trends in use of antiparkinsonian medication in our of antiparkinsonian medication in our study, it is necessary to be cautious study, it is necessary to be cautious regarding comparison of the effectiveness regarding comparison of the effectiveness of olanzapine and risperidone in reducing of olanzapine and risperidone in reducing extrapyramidal symptoms (Fig. 2 ). extrapyramidal symptoms (Fig. 2) . Specifically, physicians may have been Specifically, physicians may have been more likely to prescribe olanzapine for more likely to prescribe olanzapine for those with a higher prevalence of extrathose with a higher prevalence of extrapyramidal symptoms since this drug was pyramidal symptoms since this drug was launched with clinical data supporting launched with clinical data supporting its advantage over risperidone in lowering its advantage over risperidone in lowering the risk of these symptoms (Tran the risk of these symptoms (Tran et al et al, , 1997) . Nevertheless, olanzapine may 1997). Nevertheless, olanzapine may have a lower risk of extrapyramidal symphave a lower risk of extrapyramidal symptoms than risperidone based on the large toms than risperidone based on the large differences in the observed rates of reducdifferences in the observed rates of reduction in use of antiparkinsonian agents tion in use of antiparkinsonian agents between those initiated on olanzapine and between those initiated on olanzapine and risperidone. risperidone.
Switching to atypical antipsychotics Switching to atypical antipsychotics did not change the average daily dose did not change the average daily dose of antiparkinsonian drugs among those of antiparkinsonian drugs among those prescribed these medications. This implies prescribed these medications. This implies that switching to atypical antipsychotics that switching to atypical antipsychotics may not have mitigated the severity of may not have mitigated the severity of extrapyramidal symptoms among those extrapyramidal symptoms among those continuing to receive antiparkinsonian continuing to receive antiparkinsonian medications despite the overall reductions medications despite the overall reductions in the rate of antiparkinsonian drug use. in the rate of antiparkinsonian drug use. Those with milder extrapyramidal sympThose with milder extrapyramidal symptoms may be more likely to have discontoms may be more likely to have discontinued antiparkinsonian therapy after tinued antiparkinsonian therapy after switching to atypical antipsychotics. For switching to atypical antipsychotics. For example, among individuals in the TA example, among individuals in the TA group who received lower than the median group who received lower than the median daily dose of antiparkinsonian agents bedaily dose of antiparkinsonian agents before switching to atypical antipsychotics, fore switching to atypical antipsychotics, 42% discontinued antiparkinsonian medi-42% discontinued antiparkinsonian medication after the switch, compared with a cation after the switch, compared with a discontinuation rate of 27% among those discontinuation rate of 27% among those in the group who received higher than the in the group who received higher than the median daily dose of antiparkinsonian median daily dose of antiparkinsonian drugs before switching. However, for drugs before switching. However, for some it is possible that the antiparkinsonian some it is possible that the antiparkinsonian medication was simply neglected, leading medication was simply neglected, leading to no change in dose. to no change in dose.
Comparison with clinical trials Comparison with clinical trials
In this study, the effect of switching to olanIn this study, the effect of switching to olanzapine on the treatment of extrapyramidal zapine on the treatment of extrapyramidal symptoms was not as large as in clinical symptoms was not as large as in clinical trials (Costa e Silva trials (Costa e Silva et al et al, 2001) . Moreover, , 2001 ). Moreover, the daily dose of antiparkinsonian medithe daily dose of antiparkinsonian medication did not decrease after switching to cation did not decrease after switching to atypical antipsychotics in the community, atypical antipsychotics in the community, which contrasts with findings from prewhich contrasts with findings from previous clinical studies that daily doses of vious clinical studies that daily doses of antiparkinsonian medication were lower antiparkinsonian medication were lower in those using atypical antipsychotics than in those using atypical antipsychotics than those using typical antipsychotics (Tran those using typical antipsychotics (Tran et et al al, 1999; Costa e Silva , 1999; Costa e Silva et al et al, 2001; Inada , 2001; Inada et al et al, 2001) .
, 2001). These differences might result from These differences might result from differences in study design. Participants differences in study design. Participants in the clinical trials were typically in the clinical trials were typically younger and the observation periods were younger and the observation periods were shorter than ours. Typical antipsychotics shorter than ours. Typical antipsychotics only included haloperidol, a high-potency only included haloperidol, a high-potency antipsychotic with a high risk of extrapyraantipsychotic with a high risk of extrapyramidal symptoms, which accounted for less midal symptoms, which accounted for less than 10% of typical antipsychotic use in than 10% of typical antipsychotic use in our study. our study.
Another possible explanation for the Another possible explanation for the differences is the poor adherence of those differences is the poor adherence of those in the community compared with those in in the community compared with those in the controlled environments of clinical the controlled environments of clinical trials. In addition, physician prescribing in trials. In addition, physician prescribing in community settings might be more suscepticommunity settings might be more susceptible to other factors such as patient demand, ble to other factors such as patient demand, pharmaceutical marketing and resulting pharmaceutical marketing and resulting physicians' perceptions of benefits and risks physicians' perceptions of benefits and risks of specific medications. of specific medications.
Limitations Limitations
As the design of this observational study As the design of this observational study did not include randomisation, groups did not include randomisation, groups might have differed in demographic characmight have differed in demographic characteristics, severity and duration of disease, teristics, severity and duration of disease, or treatment course. For example, those or treatment course. For example, those switching within typical antipsychotics switching within typical antipsychotics were older and more likely to be female were older and more likely to be female than those switching from typical to atypithan those switching from typical to atypical antipsychotics. The use of low-potency cal antipsychotics. The use of low-potency typical antipsychotics with a low incidence typical antipsychotics with a low incidence of extrapyramidal symptoms was higher in of extrapyramidal symptoms was higher in the T the TT group (27%) than in the TA group T group (27%) than in the TA group (19%) before switching. Thus, it is difficult (19%) before switching. Thus, it is difficult to compare the effect of switching between to compare the effect of switching between groups, even though age and gender were groups, even though age and gender were adjusted for in our analyses. Nevertheless, adjusted for in our analyses. Nevertheless, our results are valid within groups since our results are valid within groups since we observed the same individuals over 4 we observed the same individuals over 4 years. years.
Those who switched medications might Those who switched medications might also have been different from those who also have been different from those who remained on the same treatment. In remained on the same treatment. In 14 0 14 0 Fig. 2 Rates of antiparkinsonian drug prescribing before and after switching from typical antipsychotics to
Rates of antiparkinsonian drug prescribing before and after switching from typical antipsychotics to (a) risperidone ( (a) risperidone (n n¼87) and (b) olanzapine ( 87) and (b) olanzapine (n n¼78). 78).
additional analyses of those who received additional analyses of those who received new prescriptions for antipsychotics and new prescriptions for antipsychotics and did not switch therapy, rates of antiparkindid not switch therapy, rates of antiparkinsonian drug prescribing were 10% lower sonian drug prescribing were 10% lower among new atypical antipsychotic users among new atypical antipsychotic users compared with rates observed after switchcompared with rates observed after switching to atypical antipsychotics, whereas the ing to atypical antipsychotics, whereas the rates in new recipients of typical antirates in new recipients of typical antipsychotics were not different from rates psychotics were not different from rates observed before switching to atypical antiobserved before switching to atypical antipsychotics. Those who had been switched psychotics. Those who had been switched seemed more likely to be prescribed antiseemed more likely to be prescribed antiparkinsonian drugs than those who had parkinsonian drugs than those who had not been switched, even though they not been switched, even though they commonly used atypical antipsychotics. commonly used atypical antipsychotics. In addition, switching might have In addition, switching might have resulted from several factors, including resulted from several factors, including side-effects or lack of efficacy. Our data side-effects or lack of efficacy. Our data do not permit evaluation of the reasons do not permit evaluation of the reasons for switching, which might differ between for switching, which might differ between patient groups. For example, the prescribpatient groups. For example, the prescribing of high-potency typical antipsychotics ing of high-potency typical antipsychotics (e.g. haloperidol) with a high incidence (e.g. haloperidol) with a high incidence of extrapyramidal symptoms increased of extrapyramidal symptoms increased after switching between two typical after switching between two typical antipsychotic agents (from 36% before antipsychotic agents (from 36% before switching to 42% after switching). Some switching to 42% after switching). Some of this switching between typical antiof this switching between typical antipsychotics is likely to have been caused by psychotics is likely to have been caused by reasons other than extrapyramidal sympreasons other than extrapyramidal symptoms. Therefore, we cannot infer the toms. Therefore, we cannot infer the appropriateness of switching based only on appropriateness of switching based only on the change in the rate of antiparkinsonian the change in the rate of antiparkinsonian prescribing. prescribing.
Our results from those who switched Our results from those who switched antipsychotics in primary care might antipsychotics in primary care might not be generalisable to all people with not be generalisable to all people with schizophrenia.
However, the wellschizophrenia.
However, the wellintegrated healthcare delivery system in integrated healthcare delivery system in the UK might enable general practitioners the UK might enable general practitioners to collaborate with specialists and follow to collaborate with specialists and follow their recommendations. Of those who their recommendations. Of those who switched antipsychotics in this study, switched antipsychotics in this study, 14% had been referred to specialists 14% had been referred to specialists during the 6-month period before switchduring the 6-month period before switching, whereas only 5% had been referred ing, whereas only 5% had been referred between 6 months and 1 year before between 6 months and 1 year before switching. This suggests that some switches switching. This suggests that some switches in this study might have reflected in this study might have reflected specialists' recommendations. specialists' recommendations.
We measured antiparkinsonian drug We measured antiparkinsonian drug prescribing to assess the effect of switching prescribing to assess the effect of switching on treatment of extrapyramidal symptoms. on treatment of extrapyramidal symptoms. Although antiparkinsonian drug prescribAlthough antiparkinsonian drug prescribing has been used in previous studies to asing has been used in previous studies to assess extrapyramidal symptoms (Tran sess extrapyramidal symptoms (Tran et al et al, , 1999; Costa e Silva 1999; Costa e Silva et al et al, 2001; Inada , 2001; Inada et et al al, 2001; Bobes , 2001; Bobes et al et al, 2003; Montes , 2003; Montes et al et al, , 2003) , it is only a marker and cannot accu-2003) , it is only a marker and cannot accurately reflect their incidence. Moreover, our rately reflect their incidence. Moreover, our data did not permit us to ascertain whether data did not permit us to ascertain whether clinical tests of extrapyramidal symptoms clinical tests of extrapyramidal symptoms were performed before prescription of were performed before prescription of antiparkinsonian drugs. Their prescription antiparkinsonian drugs. Their prescription might also have been influenced by practice might also have been influenced by practice variables or environmental factors. The variables or environmental factors. The results of this study should be interpreted results of this study should be interpreted in the light of these limitations. in the light of these limitations.
Our study recorded prescribing, not Our study recorded prescribing, not dispensing. Drugs recorded might not dispensing. Drugs recorded might not have been dispensed or taken by patients. have been dispensed or taken by patients. This should also be considered in the This should also be considered in the interpretation of results. interpretation of results.
Finally, we cannot exclude the possiFinally, we cannot exclude the possibility that some individuals might have bility that some individuals might have been prescribed antiparkinsonian medicabeen prescribed antiparkinsonian medications because they had Parkinson's disease, tions because they had Parkinson's disease, not because they had extrapyramidal not because they had extrapyramidal symptoms caused by antipsychotics. symptoms caused by antipsychotics. However, we do not have data on the However, we do not have data on the prevalence of Parkinson's disease in the prevalence of Parkinson's disease in the study population. study population.
Implications Implications
This study investigated changes in the use This study investigated changes in the use of antiparkinsonian medication after of antiparkinsonian medication after switching antipsychotics. We found that switching antipsychotics. We found that the magnitude of the effects of switching the magnitude of the effects of switching from typical to atypical antipsychotics on from typical to atypical antipsychotics on reducing antiparkinsonian medication use reducing antiparkinsonian medication use was considerable in community practices, was considerable in community practices, but not as large as the effects observed in but not as large as the effects observed in clinical trials. The effects of switching anticlinical trials. The effects of switching antipsychotics on antiparkinsonian medication psychotics on antiparkinsonian medication use also varied substantially between use also varied substantially between risperidone and olanzapine. The differences risperidone and olanzapine. The differences between specific atypical agents as well as between specific atypical agents as well as between typical and atypical antipsychotics between typical and atypical antipsychotics should be considered in treatment decisions should be considered in treatment decisions We should be cautious in comparing the effects of switching between groups because this was not a randomised controlled trial. because this was not a randomised controlled trial.
and policies concerning antipsychotic use and policies concerning antipsychotic use (Tamminga, 2003) . Several US Medicaid (Tamminga, 2003) . Several US Medicaid programmes require individuals to undergo programmes require individuals to undergo a trial of use of the lowest-cost atypical a trial of use of the lowest-cost atypical antipsychotic before approval of more antipsychotic before approval of more expensive agents, which may not lead to expensive agents, which may not lead to optimum control of extrapyramidal sympoptimum control of extrapyramidal symptoms (Soumerai, 2004) . Further research is toms (Soumerai, 2004) . Further research is needed on the relationship between extraneeded on the relationship between extrapyramidal symptoms and treatment adherpyramidal symptoms and treatment adherence and the quality of life of those with ence and the quality of life of those with schizophrenia, as well as on clinical outschizophrenia, as well as on clinical outcomes of cost containment policies that comes of cost containment policies that restrict access to specific antipsychotic restrict access to specific antipsychotic agents. agents. 
